Recurrent MEF2D fusions with poor prognosis have been identified in B-cell precursor ALL (BCP-ALL). The molecular mechanisms underlying the pathogenic function of MEF2D fusions are poorly understood. Here, we show that MEF2D-HNRNPUL1 (MH) knock-in mice developed a progressive disease from impaired B-cell development at the pre–pro-B stage to pre-leukemia over 10 to 12 months. When cooperating with NRASG12D, MH drove an outbreak of BCP-ALL, with a more aggressive phenotype than the NRASG12D-induced leukemia. RNA-sequencing identified key networks involved in disease mechanisms. In chromatin immunoprecipitation–sequencing experiments, MH acquired increased chromatin-binding ability, mostly through MEF2D-responsive element (MRE) motifs in target genes, compared with wild-type MEF2D. Using X-ray crystallography, the MEF2D-MRE complex was characterized in atomic resolution, whereas disrupting the MH-DNA interaction alleviated the aberrant target gene expression and the B-cell differentiation arrest. The C-terminal moiety (HNRNPUL1 part) of MH was proven to contribute to the fusion protein’s trans-regulatory activity, cofactor recruitment, and homodimerization. Furthermore, targeting MH-driven transactivation of the HDAC family by using the histone deacetylase inhibitor panobinostat in combination with chemotherapy improved the overall survival of MH/NRASG12D BCP-ALL mice. Altogether, these results not only highlight MH as an important driver in leukemogenesis but also provoke targeted intervention against BCP-ALL with MEF2D fusions.
The aim of this study was to evaluate the ability of the red blood cell distribution width (RDW) to predict prognosis and treatment response in chronic myeloid leukemia (CML)-chronic phase (CP) patients treated with tyrosine kinase inhibitor (TKIs). We retrospectively enrolled 93 newly diagnosed CML-CP patients treated with TKIs from 2009 to 2018 at the First Hospital of Lanzhou University. Patients were divided into 2 groups using an RDW of 18.65% determined by receiver operating characteristic curve analysis. We analyzed the correlation of treatment responses and the RDW compared to common scoring systems, as well as the correlation of the RDW with disease outcome, including overall survival (OS) and progression-free survival (PFS), and demographic and laboratory factors affecting outcome. Univariate analysis and Cox regression analysis were used. The median age of patients was 40 years, and 51 patients (54.8%) were men. A high RDW could predict treatment response at 3 months (P = .03) and 6 months (P = .02). The RDW was significantly lower in patients who achieved molecular response by 3 months (P < .001) and complete cytogenetic response by 6 months (P = .001) than in those who did not respond. Patients with a high RDW (>18.65%, n = 35) had significantly worse 5-year OS (77.1% vs 96.6%; P = .008) and PFS (80.0% vs 98.3%; P = .002) than those with a low RDW (≤18.65%, n = 58). Multivariate analysis demonstrated that a high RDW was an adverse predictor of OS (P = .005, HR (hazard ratio) = 9.741) and PFS (P = .009, HR = 16.735). The RDW is a readily available prognostic marker of outcome in patients with CML-CP and can predict treatment response to TKIs. Further larger and prospective studies are required.
Esophageal squamous cell carcinoma (ESCC) is often diagnosed at advanced stages due to the inherent limitations of current screening methodologies. Central to evaluating tumor invasion and prognostic assessment in ESCC is the integrity of the basement membrane (BM). However, current research on the implications of BM-related genes (BMRGs) in diagnosing ESCC remains sparse. We performed a comprehensive analysis using single-cell RNA-sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) database, alongside gene expression profiles acquired from GEO and The Cancer Genome Atlas (TCGA) databases. This identified differentially expressed BMRGs in ESCC. Employing LASSO, RF, and SVM-RFE, we selected potential BM biomarkers and crafted a diagnostic nomogram for ESCC, validated by ROC curves and AUC values. We also explored immune infiltration and biological mechanisms through consensus clustering and GSVA, and utilized single cell trajectory analysis and GSCALite to study gene distributions and pathways. In vitro experiments further elucidated the role of these genes in ESCC carcinogenesis. Here, we discovered that ESCC cell types exhibited markedly elevated BM-related scores. Our analysis pinpointed seven BM genes upregulated and linked to immune infiltration, showcasing unique gene expression profiles and varying immune cell densities across the BM-related subtypes. Furthermore, a robust positive correlation was observed between these genes expression and EMT activity. The knockdown of BGN significantly suppressed cell proliferation, migration, invasion, while also augmenting cell viability following chemotherapy drug treatment. Our study identified seven key BMRGs (BGN, LAMB3, SPARC, MMP1, LUM, COL4A1, and NELL2) and established a diagnostic nomogram for ESCC. Of noteworthy significance is the discovery of BGN as a promising drug target, indicating a novel strategy for future clinical combination therapies in ESCC.
19 December 2023 in Clinical and Translational Medicine
Background: IGH::DUX4 is frequently observed in 4% B‐cell acute lymphoblastic leukaemia patients. Regarding the IGH::DUX4‐driven transactivation and alternative splicing, which are the main reasons behind this acute leukaemia outbreak, it remains unclear how transcriptional cofactors contribute to this oncogenic process. Further investigation is required to elucidate their specific role in leukaemogenesis.Methods: In order to investigate the cofactors of IGH::DUX4, integrated mining of Chromatin immunoprecipitation (ChIP)‐sequencing and RNA‐sequencing of leukaemia cells and patient samples were conducted. Furthermore, to elucidate the synergistic interaction between transcription factor 12 (TCF12) and IGH::DUX4, knockdown and knockout experiment, mammalian two‐hybridisation assay, co‐immunoprecipitation and in situ proximity ligation assays were carried out. Additionally, to further investigate the direct interaction between TCF12 and IGH::DUX4, AI‐based structural simulations were utilised. Finally, to validate the synergistic role of TCF12 in promoting IGH::DUX4 leukaemia, cell proliferation, apoptosis and drug sensitivity experiments were performed.Results: In this study, we observed that the IGH::DUX4 target gene TCF12 might be an important cofactor/helper for this oncogenic driver. The co‐expression of IGH::DUX4 and TCF12 resulted in enhanced DUX4‐driven transactivation. Supportively, knockdown and knockout of TCF12 significantly reduced expression of IGH::DUX4‐driven target genes in leukaemia REH (a precursor B‐cell leukaemia cell line) and NALM‐6 cells (a precursor B‐cell leukaemia cell line). Consistently, in TCF12 knockout cells, the expression of structure‐based TCF12 mutant, but not wild‐type TCF12, failed to restore the TCF12–IGH::DUX4 crosstalk and the synergistic transactivation. More importantly, the breakdown in TCF12–IGH::DUX4 cooperation impaired IGH::DUX4‐driven leukaemia cell survival, caused sensitivity to the chemotherapy.Conclusions: Altogether, these results helped to define a previously unrecognised TCF12‐mediated positive self‐feedback regulatory mechanism in IGH::DUX4 leukaemia, which holds the potential to function as a pivotal drug target for the management of this particular form of leukaemia.Highlights: Transcription factor 12 (TCF12) is a new novel cofactor in IGH::DUX4 transcriptional complexes/machinery. TCF12 mediates a positive self‐feedback regulatory mechanism in IGH::DUX4‐driven oncogenic transaction. IGH::DUX4–TCF12 structure/cooperation might represent a potent target/direction in future drug design against B‐cell acute lymphoblastic leukaemia.
31 March 2021 in Acta Crystallographica Section F Structural Biology Communications
AGAP1, a key regulator of the cytoskeleton, plays a vital role in cell migration and invasion. Aberrant expression of AGAP1 is frequently associated with a variety of severe diseases, including triple-negative breast cancer (TNBC). However, the pathogenic mechanism underpinning the AGAP1-driven disease progression is yet to be understood. Here, we observed that genetic knockout of AGAP1 significantly promoted TNBC tumor growth and metastasis. This led to aberrant activation of glycolysis and tricarboxylic acid cycle (TCA) metabolic pathway in the subcutaneous xenograft model and pulmonary metastasis mouse model. Using X-ray crystallography, we determined the crystal structure of the AGAP-GLD domain in complex with GDP nucleotide (2.5 Å), revealing a previously unrecognized noncanonical GDP-binding site delineated by three relatively conserved residues, R106-F107-K108. Structure-based mutagenesis assays showed that the disruption of this GDP-binding site markedly enhanced the proliferation and migration of TNBC cells. RNA-seq transcriptome profiling in cancer cells again highlighted the glycolysis and TCA cycle regulated by AGAP1-GDP interaction. This was further supported by ECAR, OCR and glucose uptake measurements, alongside enhanced PI3K–AKT activation and PI3K dependence, as copanlisib suppressed AGAP1 loss–induced proliferation. Supportively, AGAP1 was downregulated in TNBC patients, associated with an activated immune–stromal microenvironment. The AGAP1 mutations near the GDP-binding site was often correlated with poorer patient survival, consistent with the structure-based animal experiments. Altogether, these results helped to define a previously unrecognized noncanonical GDP-binding site in AGAP1 that might play a critical role in TNBC progression.